Frontage Europe, a wholly owned subsidiary of Frontage Laboratories Inc., has relocated its bioanalytical laboratory to a new 2,500-square-meter facility near Milan, Italy. The move consolidates the company’s analytical and central laboratory operations under one roof at its site in Nerviano, about 25 kilometers from Malpensa Airport.
The new facility houses advanced analytical platforms for quantitative mass spectrometry, ligand-binding, and biomarker assays. Instruments include LC-MS/MS, Meso Scale Discovery (MSD), Quanterix Simoa HD-X, and ELISA systems, along with a recently added Lumipulse G1200 analyzer.
Frontage Europe’s bioanalytical operations function under Good Laboratory Practice (GLP) standards and are compliant with Good Clinical Practice (GCP) guidelines. The laboratory conducts bioanalytical assay validation and sample analysis in accordance with ICH M10 regulatory requirements.
In addition to its bioanalytical capabilities, the site now supports central laboratory services, including logistics and project management for clinical studies. Recent investments have expanded analytical and sample processing capacities and increased in-house storage with -80°C and -20°C freezers to improve specimen handling and turnaround times.
The company also provides custom synthesis services for radiolabeled (^14C, ^3H, ^35S) and stable-labeled (^2H, ^13C, ^15N) compounds used in metabolism and pharmacokinetic studies. These services are supported by high-resolution mass spectrometry using a Q-Exactive Orbitrap platform for both in vitro and in vivo analyses.
Frontage Europe’s new address is Viale Luigi Pasteur 10, 20014 Nerviano (MI), Italy.